Smith & Nephew plc Receives Neutral Rating from Citigroup Inc. (SN.)
Smith & Nephew plc (LON:SN.)‘s stock had its “neutral” rating reaffirmed by research analysts at Citigroup Inc. in a report released on Tuesday, Stock Ratings Network.com reports. They currently have a GBX 830 ($13.39) price objective on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew plc (LON:SN.) in a research note to investors on Friday. Separately, analysts at Credit Suisse raised their price target on shares of Smith & Nephew plc (LON:SN.) from GBX 750 ($12.10) to GBX 775 ($12.50) in a research note to investors on Wednesday, September 25th. They now have a “neutral” rating on the stock. Finally, analysts at Societe Generale cut their price target on shares of Smith & Nephew plc (LON:SN.) from GBX 695 ($11.21) to GBX 660 ($10.65) in a research note to investors on Monday, September 9th. They now have a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of GBX 775.38 ($12.51).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.